As we have embarked on our expanded mission into immuno-oncology development and commercialization, our immuno-oncology scientific advisory board (SAB) provides strategic guidance and direction for our immuno-oncology R&D programs. The SAB includes scientific and clinical advisors who have made significant contributions to advancing the field of immuno-oncology.